共 50 条
- [1] A phase 2 study on efficacy, safety and intratumoral pharmacokinetics of oral selinexor (KPT-330) in patients with recurrent glioblastoma (GBM).[J]. JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)Lassen, Ulrik NielsMau-Soerensen, MortenKung, Andrew L.Wen, Patrick Y.Lee, Eudocia QuantPlotkin, Scott R.Muhic, AidaRashal, TamiWilliams, TonyMcCauley, DilaraEllis, JoelSaint-Martin, Jean-RichardCarlson, RobertFrenkel, RanShacham, SharonMirza, Mansoor RazaKauffman, MichaelLassman, Andrew B.
- [2] INTERIM ANALYSIS DATA FROM PHASE 2 STUDY ON EFFICACY, SAFETY & INTRATUMORAL PHARMACOKINETICS OF ORAL SELINEXOR (KPT-330) IN PATIENTS WITH RECURRENT GLIOBLASTOMA (GBM)[J]. NEURO-ONCOLOGY, 2017, 19 : 14 - 14Lassman, A. B.Bent, M. J. V. D.Wen, P. Y.Walenkamp, A.Plotkin, S.Kung, A.Gardner, H.Shacham, S.Chudnovsky, A.Mau-Sorensen, P. M.
- [3] Safety, Efficacy, and Determination of the Recommended Phase 2 Dose for the Oral Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330)[J]. BLOOD, 2015, 126 (23)Chen, ChristineGarzon, RamiroGutierrez, MartinJacoby, Meagan A.Brown, PeterFlinn, IanStone, Richard M.Savoie, Mary LynnBaz, RachidGabrail, Nashat Y.Wang, MichaelMartin, PeterSiegel, DavidMau-Sorensen, MortenAndreef, MichaelMarshall, TraceySaint-Martin, Jean-RichardCarlson, RobertShacham, SharonKauffman, MichaelKuruvilla, John
- [4] FINAL RESULTS OF A PHASE 2 STUDY OF EFFICACY, SAFETY AND INTRATUMORAL PHARMACOKINETICS (PK) OF SELINEXOR MONOTHERAPY IN RECURRENT GLIOBLASTOMA (RGBM)[J]. NEURO-ONCOLOGY, 2020, 22 : 46 - 46Lassman, AndrewWen, Patrickvan den Bent, MartinPlotkin, ScottWalenkamp, AnnemiekGreen, AdamWang, HongweiLi, KaiLiu, YangXu, HongmeiShah, JatinKauffman, MichaelShacham, SharonMau-Soerensen, Morten
- [5] A Phase II Study of the Efficacy and Safety of Oral Selinexor in Recurrent Glioblastoma[J]. CLINICAL CANCER RESEARCH, 2022, 28 (03) : 452 - 460Lassman, Andrew B.Wen, Patrick Y.van den Bent, Martin J.Plotkin, Scott R.Walenkamp, Annemiek M. E.Green, Adam L.Li, KaiWalker, Christopher J.Chang, HuaTamir, SharonHenegar, LeahShen, YaoAlvarez, Mariano J.Califano, AndreaLandesman, YosefKauffman, Michael G.Shacham, SharonMau-Sorensen, Morten
- [6] KCP-330-005/SIGN: A PHASE II, OPEN-LABEL STUDY OF EFFICACY AND SAFETY OF THE SELECTIVE INHIBITOR OF NUCLEAR EXPORT (SINE) KPT-330 (SELINEXOR) IN PATIENTS WITH ADVANCED GYNAECOLOGIC MALIGNANCIES[J]. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2014, 24 (09) : 1182 - 1183Vergote, I.Lund, B.Ujmajuridze, Z.Havsteen, H.Rashal, T.Marshall, T.McCartney, J.Kauffman, M.Shacham, S.Mirza, M. R.
- [7] Preclinical efficacy of the novel, oral Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330) on castration resistant prostate cancer[J]. CANCER RESEARCH, 2014, 74 (19)Maity, Sankar NarayanWu, GuanglinLu, Jing-FangHoang, AnhLandesman, YosefMcCauley, DilaraShacham, SharonKauffman, Michael G.Aparicio, Ana M.Efstathiou, EleniAraujo, John C.Logothetis, Christopher J.
- [8] Quality of life analyses in patients with multiple myeloma: results from the Selinexor (KPT-330) Treatment of Refractory Myeloma (STORM) phase 2b study[J]. BMC Cancer, 21Gabriel TremblayPatrick DanieleJanis BreezeLingling LiJatin ShahSharon ShachamMichael KauffmanMonika EngelhardtAjaj ChariAjay NookaDan VoglMaria GavriatopoulouMeletios-Athanasios DimopoulosPaul RichardsonNoa BiranDavid SiegelPhilip VlummensChantal DoyenThierry FaconMohamad MohtyNathalie MeulemanMoshe LevyLuciano CostaJames E. HoffmanMichel DelforgeDavid KaminetzkyKatja WeiselMarc RaabDavid DingliSascha TuchmanFrenzel LaurentRavi VijGary SchillerPhilippe MoreauJoshua RichterMartin SchrederKlaus PodarTerri ParkerRobert Frank CornellKarlin LionelSylvain ChoquetJagannath Sundar
- [9] QUALITY OF LIFE ANALYSES IN PATIENTS WITH MULTIPLE MYELOMA: RESULTS FROM THE SELINEXOR (KPT-330) TREATMENT OF REFRACTORY MYELOMA (STORM) PHASE 2B STUDY[J]. VALUE IN HEALTH, 2020, 23 : S77 - S77Breeze, J.Mehta, J.Tremblay, G.Shacham, S.Shah, J.Li, L.Kauffman, M.Jagannath, S.
- [10] Quality of life analyses in patients with multiple myeloma: results from the Selinexor (KPT-330) Treatment of Refractory Myeloma (STORM) phase 2b study[J]. BMC CANCER, 2021, 21 (01)Tremblay, GabrielDaniele, PatrickBreeze, JanisLi, LinglingShah, JatinShacham, SharonKauffman, MichaelEngelhardt, MonikaChari, AjajNooka, AjayVogl, DanGavriatopoulou, MariaDimopoulos, Meletios-AthanasiosRichardson, PaulBiran, NoaSiegel, DavidVlummens, PhilipDoyen, ChantalFacon, ThierryMohty, MohamadMeuleman, NathalieLevy, MosheCosta, LucianoHoffman, James E.Delforge, MichelKaminetzky, DavidWeisel, KatjaRaab, MarcDingli, DavidTuchman, SaschaLaurent, FrenzelVij, RaviSchiller, GaryMoreau, PhilippeRichter, JoshuaSchreder, MartinPodar, KlausParker, TerriCornell, Robert FrankLionel, KarlinChoquet, SylvainSundar, Jagannath